Cannabis

Auxly is Ready to go for 2.0: Reveals Portfolio of Cannabis Products

Published

5 years ago

December 16, 2019

GlobeNewswire

TORONTO, Dec. 16, 2019 (GLOBE NEWSWIRE) — Auxly Cannabis Group Inc. (TSX.V – XLY) (“Auxly” or the “Company”) today announced the unveiling of its “Cannabis 2.0” products in vape, chocolate and chewable formats which are legally available for sale beginning today under its signature brands, Kolab Project, Foray and Dosecann. To view Auxly’s 2.0 product launch video, click here.

“Having our initial suite of Cannabis 2.0 products ready to go on the first day sales are legal in Canada is a huge milestone for our company,” said Hugo Alves, CEO, Auxly. “Our mission is to make branded cannabis products that consumers love and grow to trust. Our experts at Dosecann have developed high-quality vapes, chocolates and chewables with consumer safety and enjoyment as our top priorities. We are excited to introduce Canadian consumers to our products and our brands on the launch of Cannabis 2.0 and will continue to roll out new and innovative products in the coming quarters as we look to lead, not follow, in the 2.0 market and beyond.”

Auxly’s In-House Brands – Targeting a Broad Spectrum of Cannabis Consumers

Auxly has taken a consumer-centric approach to building a winning portfolio of brands and products. Auxly’s four proprietary brands: Kolab Project, Foray, Dosecann and Robinsons, address key market segments and multiple price points across wellness and adult-use markets.

The Company’s initial product portfolio will be launched under three of the Company’s four brands – Kolab Project, Foray and Dosecann. Outlined in the table below is a breakdown by brand and format. The launch of the Robinsons brand will coincide with the release of Robinsons’ premium dried flower produced at its craft indoor facility in Kentville, Nova Scotia. The Company intends to develop a line of premium cannabis products under the Robinsons brand based on the output of its Robinsons Outdoor Grow (announced by the Company on November 15, 2019) located in Hortonville, Nova Scotia.

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

^{*Products expected to be online Q2 2020}
^{** Products expected to be online Q3 2020}

View Auxly’s complete product catalogue on the Company’s website at www.auxly.com or by clicking here.

Diverse Brand Platform and 2.0 Product Offering

Kolab Project

Kolab Project is a platform dedicated to art, design and culture. Its mission is to provide Canadians with a carefully curated selection of exceptional cannabis products, while championing high quality, purposeful goods produced in collaboration with culturally relevant creators. The brand aims to connect with those actively in the cannabis category that have an appreciation for the positive impact that art, culture and design have on humanity.

Vapes
Kolab Project vape pens will be offered in several different profiles, specifically high-potency THC and CBD formulations. Kolab Project’s vapes contain only pure, high-grade cannabis distillate and botanical terpenes and do not contain any other ingredients. Kolab Project’s THC formulations and terpene blends were inspired by popular strains and the potency and terpenes are tailored to a more experienced cannabis consumer.

Kolab Project vape pens will initially be available as cartridges and disposables in indica, sativa, and hybrid varieties, as well as a CBD variety in a disposable format.

Soft Chews
Kolab Project’s soft chews are designed and developed to deliver robust, sophisticated flavours for the cannabis edible connoisseur. Free from artificial ingredients or animal products, this curated collection of soft chews is perfect for anyone seeking a mindful journey outside the norm.

Kolab Project soft chews will be available in Grapefruit Hibiscus, Lemon Lavender and Apple Green Tea flavours and in THC-dominant, balanced, and CBD-dominant packs. The chews are delicious, high quality, vegan and gluten-free. Kolab Project soft chews are evenly dosed in each piece and conveniently sized.

Foray

Foray is an accessible entry point for anybody — at any stage of their cannabis journey. Designed for the curious, Foray is an approachable brand that aims to both celebrate and educate one’s foray into cannabis, ultimately inviting them to see cannabis differently. The legalization of cannabis in Canada brings tremendous opportunity to educate and introduce (or reintroduce) cannabis to a new class of consumers and Foray aims to be a trusted provider and guide through a consumer’s cannabis experience.

Vapes
Foray brings a range of high-quality vape products to market in slightly lower THC potency, containing only high-grade cannabis distillate and carefully selected botanical terpene blends to ensure a pleasant experience for a consumer’s entry into the category. Foray vape pens do not contain any other ingredients. Vape cartridge formats will be available in sativa, indica, hybrid and balanced formulations, while its disposable formats will also include a CBD variety.

Chocolates
Foray’s chocolates are made exclusively from premium single origin and Belgian chocolates, expertly selected and blended to make a consumer’s Foray into cannabis luxurious and delicious. Made with all-natural ingredients and no artificial flavours, Foray chocolates will initially come in three varieties – Dark Chocolate, Vanilla Chai and Salted Caramel. Foray chocolates will initially be available in 10mg of THC per square or 2.5mg of THC per four square serving sizes. Additionally, the Salted Caramel chocolate will be available in a balanced THC & CBD formulation.

Foray’s Dark chocolate is made with a perfectly balanced, premium, single origin Mexican chocolate that displays complex notes of cinnamon, hazelnut, coffee and gingerbread. Consumers are encouraged to savor their experience as the flavours of this subtly bittersweet chocolate unfold on their palate.

Foray’s Vanilla Chai chocolate is made with a single origin Ghanaian chocolate delicately flavoured with chai spices and vanilla. Also displaying notes of cocoa, red fruit, and chestnut, this premium chocolate has a rich, creamy mouthfeel.

Foray’s Salted Caramel chocolate is made from an expertly selected blend of premium white and milk chocolates, enhanced with notes of rich caramel with a subtle, salty finish. With a balanced profile of THC and CBD, this chocolate is a perfect indulgence.

Soft Chews
Foray’s soft chews are crafted to deliver deliciously bright, juicy flavours. These pectin-based chews, free from any artificial ingredients or animal products, offer a range of potencies so they can be enjoyed by anyone.

Foray soft chews will initially be available in Raspberry Vanilla, Peach Mango and Pineapple Orange flavours in THC-dominant, balanced, and CBD-dominant packs.

Like Kolab Project’s soft chews, Foray’s soft chews are made with the highest quality traceable, vegan ingredients combined with ultra-pure cannabis distillate produced in-house at Dosecann. Foray’s rich soft chews offer consumers unparalleled flavour and the security that each piece has been precisely dosed to ensure a satisfying experience.

Dosecann

Dosecann is a wellness brand built on pillars of quality, safety and efficacy. Backed by science and advanced research and development, Dosecann products are driving today’s innovation and establishing tomorrow’s standards. Dosecann is cannabis – down to a science™.

Dosecann’s “Cannabis 1.0” oil in bottle and spray formats are currently available for sale, with capsule and lozenge formats expected in Q2 2020 and topicals in Q3 2020.

Auxly Cares About Consumer Safety

Auxly is committed to ensuring consumers have access to quality products they can trust. For that reason, Auxly’s Safety Board, on which Imperial Brands PLC’s Group Science and Regulatory Affairs Director sits, oversees our entire product development life cycle, carefully evaluates and monitors all of our products before and after they are released for sale and ensures that consumers have access to clear and accurate information on product risks.

Vape Development

Like all of Auxly’s branded cannabis products, its vapes have been developed with quality, safety and efficacy at the heart of the product development process. The Company has gone above and beyond applicable regulatory requirements with both its hardware and its formulations, including conducting voluntary emissions testing at a leading third-party lab, to earn the trust of Canadian consumers.

All of Auxly’s products are formulated and manufactured at Dosecann, Auxly’s commercial scale extraction, analytical testing, product development and manufacturing hub located in Charlottetown, Prince Edward Island. Dosecann, in collaboration with KGK Science Inc., the Company’s wholly-owned contract research organization, will continue to push industry standards in terms of product safety, quality, efficacy and innovation.

ON BEHALF OF THE BOARD

“Hugo Alves” CEO

About Auxly Cannabis Group Inc. (TSX.V: XLY) (OTCQX: CBWTF)

Auxly is an international cannabis company dedicated to bringing innovative, effective, and high-quality cannabis products to the medical, wellness and adult-use markets. Auxly’s experienced team of industry first-movers and enterprising visionaries has secured a diversified supply of raw cannabis, strong clinical, scientific and operating capabilities and leading product research and development infrastructure in order to create trusted products and brands in an expanding global market.

Learn more at www.auxly.com and stay up to date at Twitter: @AuxlyGroup; Instagram: @auxlygroup; Facebook: @auxlygroup; LinkedIn: company/auxlygroup/.

Investor Relations:

For investor enquiries please contact our Investor Relations Team:
Email: [email protected]
Phone: 1.833.695.2414

Media Enquiries (only):

For media enquiries or to set up an interview please contact:
Email: [email protected]

Notice Regarding Forward Looking Information:

This news release contains certain “forward-looking information” within the meaning of applicable Canadian securities law. Forward-looking information is frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. This information is only a prediction. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking information throughout this news release. Forward-looking information includes, but is not limited to: the successful production and launch of the Company’s new derivative products; the timeline for the launch of additional product formats; the Company’s execution of its product development and commercialization strategy; consumer preferences; political change, future legislative and regulatory developments involving cannabis and cannabis products; and competition and other risks affecting the Company in particular and the cannabis industry generally.

A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking information in this release including, but not limited to, whether: Kolab Project and Dosecann are able to maintain their sales licenses and are able to obtain and maintain all other necessary governmental and regulatory authorizations and permits to conduct business; the acceptance and demand for future Company products by consumers and provincial purchasers; and general economic, financial market, regulatory and political conditions in which the Company operates will remain the same. Additional risk factors are disclosed in the revised annual information form of the Company for the financial year ended December 31, 2017 dated May 24, 2018.

New factors emerge from time to time, and it is not possible for management to predict all of those factors or to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The forward-looking information in this release is based on information currently available and what management believes are reasonable assumptions. Forward-looking information speaks only to such assumptions as of the date of this release. In addition, this release may contain forward-looking information attributed to third party industry sources, the accuracy of which has not been verified by the Company. The purpose of forward-looking information is to provide the reader with a description of management’s expectations, and such forward-looking information may not be appropriate for any other purpose. Readers should not place undue reliance on forward-looking information contained in this release.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Three photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/288d4ac2-fa20-49d6-8100-faca35ec16dd

https://www.globenewswire.com/NewsRoom/AttachmentNg/3c424577-4bd0-47a8-ac4c-00fd081973f6

https://www.globenewswire.com/NewsRoom/AttachmentNg/b712dd0e-d046-495f-9a37-8cc5bad5808d

Cannabis

IM Cannabis Announces Appointment of Shmulik Arbel to Board of Directors

Published

1 day ago

September 11, 2024

CISION (PR Newswire)

im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors

TORONTO and GLIL YAM, Israel, Sept. 11, 2024 /PRNewswire/ — IM Cannabis Corp. (“IMC” or the “Company“) (NASDAQ: IMCC) (CSE: IMCC), a leading medical cannabis company with operations in Israel and Germany, is pleased to announce that Mr. Shmulik Arbel has been appointed to the Company’s board of directors (the “Board“) effective September 9, 2024. Mr. Arbel brings a wealth of experience in strategic plans that drive profitability, as well as, finance and corporate governance, further strengthening the company’s commitment to driving growth while focusing on sustainable profitability.

“We are thrilled to welcome Shmulik to our Board of Directors,” said Oren Shuster, Chief Executive Officer of IM Cannabis. “Shmulik’s extensive international experience at Leumi, coupled with his proven track record in banking and finance will be invaluable as we continue to deliver on our strategic initiatives.”

Mr. Arbel retired as Deputy CEO from Leumi, Israel’s largest banking group, in April 2023, where he was instrumental in business growth and leading the service revolution. With over 25 years of experience at Leumi, Arbel has held senior roles throughout the organization, such as head of retail banking, head of the corporate division, and as chairman of Leumi UK. With key roles in Israel, New York and London, Mr. Arbel has a wide view on international business.

“I am honored to join the Board of Directors at IMCC,” said Mr. Arbel. “I look forward to leveraging my experience in banking and finance, providing guidance as IMCC continues to establish itself as the go-to brand in the cannabis world. I look forward to contributing to the company’s growth.”

Arbel holds a BA and MBA from Tel Aviv University.

About IM Cannabis Corp.

IMC (Nasdaq: IMCC) (CSE: IMCC) is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The Company has focused its resources to achieve sustainable and profitable growth in its highest value markets, Israel and Germany. The Company leverages a transnational ecosystem powered by a unique data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the Company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IMC ecosystem operates in Israel through its commercial relationship with Focus Medical Herbs Ltd., which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of IMC products throughout the entire value chain. In Germany, the IMC ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

Disclaimer for Forward-Looking Statements

This press release contains forward-looking information or forward-looking statements under applicable Canadian and United States securities laws (collectively, “forward-looking statements“). All information that addresses activities or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “likely” and “intend” and statements that an event or result “may”, “will”, “should”, “could” or “might” occur or be achieved and other similar expressions. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. In the press release, such forward-looking statements include, but are not limited to, statements relating to: the stated benefits Mr. Arbel’s appointment, including the further strengthening the Company’s commitment to driving growth in the German market while focusing on sustainable profitability; and Mr. Arbel’s international experience and track record in banking and finance will be invaluable to the Company.

Forward-looking statements are based on assumptions that may prove to be incorrect, including but not limited to: the Company’s ability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance becoming invaluable to the Company.

The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the failure of the Company to comply with applicable regulatory requirements in a highly regulated industry; unexpected changes in governmental policies and regulations in the jurisdictions in which the Company operates; the Company’s ability to continue to meet the listing requirements of the Canadian Securities Exchange and the NASDAQ Capital Market; any unexpected failure to maintain in good standing or renew its licenses; the ability of the Company and its subsidiaries (collectively, the “Group“) to deliver on their sales commitments or growth objectives; the reliance of the Group on third-party supply agreements to provide sufficient quantities of medical cannabis to fulfil the Group’s obligations; the Group’s possible exposure to liability, the perceived level of risk related thereto, and the anticipated results of any litigation or other similar disputes or legal proceedings involving the Group; the impact of increasing competition; any lack of merger and acquisition opportunities; adverse market conditions; the inherent uncertainty of production quantities, qualities and cost estimates and the potential for unexpected costs and expenses; risks of product liability and other safety-related liability from the usage of the Group’s cannabis products; supply chain constraints; reliance on key personnel; the risk of defaulting on existing debt; risks surrounding war, conflict and civil unrest in Eastern Europe and the Middle East, including the impact of the Israel-Hamas war on the Company, its operations and the medical cannabis industry in Israel; risks associated with the Company focusing on the Israel and Germany markets; the inability of the Company to achieve sustainable profitability and/or increase shareholder value; the inability of the Company to actively manage costs and/or improve margins; the inability of the company to grow and/or maintain sales; the inability of the Company to meet its goals and/or strategic plans; the inability of the Company to reduce costs and/or maintain revenues; the Company’s inability to take advantage of the legalization of medicinal cannabis in Germany; and the Company’s inability to realize upon the stated benefits Mr. Arbel’s appointment; and Mr. Arbel’s international experience and track record in banking and finance not becoming valuable to the Company.

Please see the other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual report dated March 28, 2024, which is available on the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and Edgar at www.sec.gov/edgar. Any forward-looking statement included in this press release is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward looking information is made. The Company does not undertake any obligation to update forward-looking statements except as required by applicable securities laws. Investors should not place undue reliance on forward-looking statements. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement.

Company Contact:

Anna Taranko, Director Investor & Public Relations
IM Cannabis Corp.
+49 157 80554338
[email protected]

Oren Shuster, CEO
IM Cannabis Corp.
[email protected]

Logo: https://mma.prnewswire.com/media/1742228/IM_Cannabis_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/im-cannabis-announces-appointment-of-shmulik-arbel-to-board-of-directors-302244961.html

Cannabis

One World Products Issues Shareholder Update Letter

Published

1 day ago

September 11, 2024

GlobeNewswire

Cannabis

Europe Medical Cannabis Market Forecast 2024-2032: Tilray, Aurora Cannabis, and GW Pharmaceuticals Dominate the Market Landscape

Published

2 weeks ago

August 29, 2024

GlobeNewswire

Dublin, Aug. 29, 2024 (GLOBE NEWSWIRE) — The “Europe Medical Cannabis Oil Market Size, Industry Dynamics, Opportunity Analysis and Forecast 2024-2032.” report has been added to ResearchAndMarkets.com’s offering.

The Europe Medical Cannabis Oil market is poised for significant growth, projected to escalate from US$ 0.91 billion in 2023 to US$ 2.40 billion by 2032, advancing at a CAGR of 12.08%. In this comprehensive research report, the market is analyzed by:

Derivatives;
Source;
Application;
Route of Administration;
End-user;
Distribution Channel; and
Country.

Market Highlights Identified in the Report

Progressive legalization across Europe is creating a favorable regulatory environment, enhancing market expansion for medical cannabis oil products.
Germany leads the market with a robust infrastructure and supportive regulations, while other countries like the UK, Italy, and Spain show significant growth potential based on evolving regulatory landscapes and market dynamics.
Key players such as Tilray, Aurora Cannabis Inc., and GW Pharmaceuticals dominate the market, emphasizing research, strategic partnerships, and innovation to maintain competitive edge amidst evolving industry dynamics.

The medical cannabis oil market has experienced substantial growth as legalization and acceptance of cannabis-based treatments expand globally. Cannabis oil, derived from the cannabis plant through extraction methods, contains cannabinoids such as THC and CBD, known for their therapeutic properties. Increasing recognition of cannabis oil’s potential in alleviating symptoms of various medical conditions, including chronic pain, epilepsy, and anxiety disorders, has driven its adoption in medical settings.

Governments in several countries are progressively legalizing medical cannabis, creating a conducive regulatory environment for market expansion. Additionally, growing consumer awareness about alternative and natural therapies has fueled the demand for cannabis oil products. The market is characterized by diverse product offerings, including full-spectrum and CBD-isolate oils, catering to different therapeutic needs and preferences.

Despite regulatory challenges and stigma associated with cannabis, the medical cannabis oil market continues to evolve, driven by ongoing research, favorable legislative changes, and shifting attitudes toward cannabis-based therapies in healthcare.

Regional Insights

Germany is likely to maintain its leadership position in the European medical cannabis oil market due to its established infrastructure, supportive regulations, and strong healthcare system. Germany legalized medical cannabis in 2017, giving the market a head start compared to many other European countries. This established infrastructure and experience position Germany as a leader in the field. As awareness and acceptance of medical cannabis increase, the number of patients seeking treatment in Germany is steadily rising. This fuels market growth and incentivizes further investment in research and development.

Germany’s regulatory framework for medical cannabis is considered relatively patient-friendly compared to some other European countries. This facilitates access for patients with qualifying conditions. The UK legalized medical cannabis in 2018 and is experiencing an increase in patient access programs. This, coupled with ongoing research, could lead to significant market growth. Italy legalized medical cannabis in 2006 but has faced challenges with availability. As regulations become more streamlined and patient access expands, the Italian market holds significant growth potential. Spain has a well-established medical cannabis industry with a focus on domestic production. As regulations evolve and export opportunities increase, the Spanish market could see a boost.

Competitive Landscape

The Medical Cannabis Oil market is characterized by a vigorous competitive landscape, with prominent entities like Tilray, Aurora Cannabis Inc., GW Pharmaceuticals, Almiral, Bedrocan, and others at the forefront, collectively accounting for approximately 41 % of the overall market share. This competitive milieu is fueled by their intensive efforts in research and development as well as strategic partnerships and collaborations, underscoring their commitment to solidifying market presence and diversifying their offerings.

The primary competitive factors include pricing, product caliber, and technological innovation. As the Medical Cannabis Oil industry continues to expand, the competitive fervor among these key players is anticipated to intensify. The impetus for ongoing innovation and alignment with evolving customer preferences and stringent regulations is high. The industry’s fluidity anticipates an uptick in novel innovations and strategic growth tactics from these leading corporations, which in turn propels the sector’s comprehensive growth and transformation.

Key Topics Covered

Chapter 1. Research Framework
Chapter 2. Research Methodology
Chapter 3. Executive Summary: Europe Medical Cannabis Oil Market
Chapter 4. Europe Medical Cannabis Oil Market Overview
Chapter 5. Europe Medical Cannabis Oil Market Analysis, by Derivatives
Chapter 6. Europe Medical Cannabis Oil Market Analysis, by Source
Chapter 7. Europe Medical Cannabis Oil Market Analysis, by Application
Chapter 8. Europe Medical Cannabis Oil Market Analysis, by Route of Administration
Chapter 9. Europe Medical Cannabis Oil Market Analysis, by End-user
Chapter 10. Europe Medical Cannabis Oil Market Analysis, by Distribution Channel
Chapter 11. Europe Medical Cannabis Oil Market Analysis, by Country
Chapter 12. The UK Medical Cannabis Oil Market Analysis
Chapter 13. Germany Medical Cannabis Oil Market Analysis
Chapter 14. The Netherlands Medical Cannabis Oil Market Analysis
Chapter 15. Italy Medical Cannabis Oil Market Analysis
Chapter 16. Spain Medical Cannabis Oil Market Analysis
Chapter 17. Poland Medical Cannabis Oil Market Analysis
Chapter 18. Rest of Europe Medical Cannabis Oil Market Analysis
Chapter 19. Company Profiles (Company Overview, Financial Matrix, Key Product Landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

A selection of companies mentioned in this report includes, but is not limited to:

Aurora Cannabis Inc.
Bedrocan
Biocann
BIOTA Biosciences LLC
Cannamedical
Mary Jane CBD
Sanity Group GmbH
Tilray
Valcon Medical

For more information about this report visit https://www.researchandmarkets.com/r/dh7q46

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.